Geron Co. (NASDAQ:GERN) Shares Sold by RA Capital Management L.P.

RA Capital Management L.P. lessened its holdings in Geron Co. (NASDAQ:GERN - Free Report) by 30.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,285,755 shares of the biopharmaceutical company's stock after selling 13,916,670 shares during the quarter. Geron comprises approximately 1.7% of RA Capital Management L.P.'s investment portfolio, making the stock its 19th largest holding. RA Capital Management L.P. owned 5.34% of Geron worth $146,577,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Csenge Advisory Group purchased a new stake in shares of Geron in the second quarter worth about $66,000. Baader Bank Aktiengesellschaft purchased a new stake in Geron during the second quarter worth $86,000. Values First Advisors Inc. purchased a new position in Geron in the second quarter valued at $115,000. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Geron during the 2nd quarter worth about $1,076,000. Finally, Bank of New York Mellon Corp grew its position in shares of Geron by 26.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,016,622 shares of the biopharmaceutical company's stock valued at $8,550,000 after acquiring an additional 415,883 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Trading Down 1.0 %

GERN stock traded down $0.04 during trading on Thursday, reaching $3.96. 3,333,511 shares of the stock were exchanged, compared to its average volume of 10,230,560. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -12.50 and a beta of 0.51. The business has a 50 day moving average price of $4.14 and a 200-day moving average price of $4.33. Geron Co. has a 1 year low of $1.64 and a 1 year high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. During the same period in the prior year, the business posted ($0.08) earnings per share. The firm's revenue for the quarter was up 17138.4% compared to the same quarter last year. On average, research analysts predict that Geron Co. will post -0.25 earnings per share for the current year.

Analyst Ratings Changes

GERN has been the topic of several research analyst reports. HC Wainwright assumed coverage on Geron in a report on Tuesday, November 5th. They issued a "buy" rating and a $8.00 price objective on the stock. Scotiabank started coverage on shares of Geron in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $6.00 target price on the stock. Leerink Partners assumed coverage on shares of Geron in a research report on Monday, September 9th. They set an "outperform" rating and a $7.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Geron in a research report on Friday, August 9th. Finally, Leerink Partnrs raised Geron to a "strong-buy" rating in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $7.05.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.